Product Description
For restoring penile erections in patients with erectile dysfunction
Mechanisms of Action: CRFR Antagonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for PF-00592379](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Erectile Dysfunction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2005-004648-30 | P2 |
Completed |
Erectile Dysfunction |
2006-06-29 |
|
A7771002 | P2 |
Completed |
Erectile Dysfunction |
None |